Fig. 5: PC7A and cGAMP show synergistic antitumour efficacy in tumour-bearing mice.
From: Prolonged activation of innate immune pathways by a polyvalent STING agonist
a–f, MC38 (a–c) and TC-1 (d–f) tumour-bearing mice were injected intratumourally (i.t.; arrows) with 5% glucose (mock), cGAMP (2.5 μg), PC7A NPs (50 μg) or cGAMP-loaded PC7A NPs at the indicated time points. Mean tumour volume (a,d), Kaplan–Meier survival curves (b,e) and spider plots of individual tumour growth curves (c,f) are shown. PC7A NPs or cGAMP alone offer some degree of immune protection. cGAMP-loaded PC7A NPs confer a synergistic antitumour immune response, with significantly improved survival; 4 out of 7 mice in the MC38 model were tumour-free (TF). In the tumour growth studies (a and d), data are mean ± s.e.m. n = 7 (mock), n = 6 (cGAMP), n = 7 (PC7A) and n = 7 (cGAMP–PC7A) biologically independent mice in each tumour model. For a and d, statistical analysis was performed using two-tailed Student’s t-tests (versus mock). For b and e, statistical analysis was performed using Mantel–Cox tests.
